NuNexus Bio

NuNexus Bio is an emerging medical-technology company advancing a portfolio of regenerative therapeutics and bio-detection platforms built to protect and restore the health of the warfighter and their families. Our founding team pairs two decades of medtech commercialization experience and biomaterials expertise with nearly a decade of federal acquisition service for military partners — a combination assembled to move promising early science across the hardest gap in translation: from the laboratory bench to a fielded, FDA-regulated product. Our regenerative medicine pipeline targets the musculoskeletal and traumatic injuries that drive lost duty days and long-term disability across the force. Lead programs include a tissue-penetrating hyaluronic acid technology that preserves injured cartilage and soft tissue near the point of injury, marine-collagen and extracellular-matrix scaffolds for bone and tissue repair to accelerate healing. In parallel, our bio-detection platform delivers rapid, low-cost colorimetric sensor arrays for detection at the point of need in austere, resource-constrained environments. Across every program, NuNexus is defined by the same disciplines: rigorous science developed with leading academic, scientific, VA and military research partners, a deliberate regulatory and manufacturing pathway, and a focus on capabilities that matter in pre-hospital and operational settings. As a non-traditional defense contractor and small business, we combine the agility to innovate quickly with the federal fluency to deliver responsibly — so better care reaches those who serve, and the families who stand behind them.